Global Allergy Immunotherapies Market Size to Reach USD 7.5 Billion by 2033 - IMARC Group

Global Allergy Immunotherapies Market Statistics, Outlook and Regional Analysis 2025-2033       

The global allergy immunotherapies market size was valued at USD 3.4 Billion in 2024, and it is expected to reach USD 7.5 Billion by 2033, exhibiting a growth rate (CAGR) of 8.29% from 2025 to 2033.

The global rise in the prevalence of allergic illnesses is a significant driver of the allergy immunotherapies market. Allergies, including allergic rhinitis, asthma, and food allergies, have become increasingly frequent all over the world, particularly in industrialized nations. For instance, according to the World Health Organization (WHO), asthma affected about 262 million people in 2019 and claimed 455000 lives. Similarly, according to an article published by the Asthma and Allergy Foundation of America, nearly 28 million people in the U.S. have asthma. This equals about 1 in 12 people. This rising patient population necessitates efficient long-term treatment solutions, which increases the demand for allergy immunotherapies that promise allergen desensitization and a potential reduction in the intensity of allergic reactions.

Moreover, continuous R&D has led to advanced immunotherapy products, including sublingual tablets and injections, that offer better efficacy and convenience. For instance, in January 2023, ALK, a global pharmaceutical company that focuses on the prevention, diagnosis, and treatment of allergies, announced that the U.S. Food and Drug Administration (FDA) approved ODACTRA® (House Dust Mite Allergen Extract) tablet for sublingual use for the treatment of HDM-induced allergic rhinitis in a person aged between 12-17. Furthermore, technological advancements in allergy immunotherapies have revolutionized the approach and effectiveness of treatments for allergic diseases. Innovations such as peptide-based immunotherapies and recombinant allergens mark a significant departure from traditional methods, offering a more personalized and precise treatment pathway. For instance, in October 2024, Spima Therapeutics SAS announced its debut with a focus on developing novel peptide-based immunotherapies for difficult-to-target patients. Peptide-based therapies, for instance, utilize small peptides that represent parts of the allergen proteins to induce tolerance without triggering a full immune response, thereby minimizing the risk of severe reactions that are sometimes seen with whole-allergen immunotherapies. For example, according to the IMARC GROUP, the global peptide therapeutics market has reached US$ 42.8 Billion in 2023 and is projected to reach US$ 86.9 Billion by 2032, exhibiting a CAGR of 7.9% during 2024-2032.

Global Allergy Immunotherapies Market Statistics, By Region

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, Europe accounted for the largest market share due to a combination of high allergy prevalence, advanced healthcare infrastructure, and proactive regulatory policies. The region has a notably high incidence of allergic disorders among its population, including respiratory allergies such as hay fever and asthma. For instance, according to an article published by the European Respiratory Society, asthma affects around 10 million people under the age of 45 in Europe.

Europe Allergy Immunotherapies Market Trends:

The prevalence of asthma in the European Union (EU) is around 8.2% in adults and 9.4% in children. This drives a strong demand for effective and long-term treatment solutions such as immunotherapy. European countries benefit from robust healthcare systems that are well-equipped to administer advanced treatments and are supported by comprehensive insurance coverage that often includes allergy immunotherapies. Moreover, Europe has been at the forefront in the adoption of innovative medical practices, with several European countries pioneering the research and development of new immunotherapy treatments.

North America Allergy Immunotherapies Market Trends:

A substantial portion of the North American population suffers from various allergic disorders, including allergic rhinitis, asthma, and food allergies. For instance, according to the Asthma and Allergy Foundation of America, in 2021, almost 81 million people in the United States were diagnosed with seasonal allergic rhinitis (hay fever). This equates to around 26% (67 million) of adults and 19% (14 million) of children. This rising prevalence has heightened the demand for effective treatment options, thereby propelling the growth of the allergy immunotherapy market.

Asia Pacific Allergy Immunotherapies Market Trends:

The region is witnessing an increase in allergic conditions such as rhinitis, asthma, and food allergies. For instance, according to the Global Asthma Report 2022, approximately 35 million of India's 1.36 billion population suffer from asthma. This surge is attributed to factors like urbanization, environmental pollution, and lifestyle changes, leading to a higher demand for effective allergy treatments.

Middle East and Africa Allergy Immunotherapies Market Trends:

Governments in the MEA region is investing in healthcare infrastructure and implementing policies to improve access to allergy treatments. For instance, under Vision 2030, the Saudi government intended to invest more than US $65 billion in healthcare infrastructure development, reorganization and privatization of health services and insurance, the establishment of 21 "health clusters" across the kingdom, and the expansion of e-health services. These initiatives facilitate market growth by increasing the availability and affordability of immunotherapy options.

Latin America Allergy Immunotherapies Market Trends:

The region has witnessed a rise in allergic conditions, such as allergic rhinitis, asthma, and food allergies. For instance, according to an article published by an article published by the National Library of Medicine, every year, more than 120,000 people in Brazil are hospitalized due to asthma. This surge is leading to a higher demand for effective treatments like immunotherapy.

Top Companies Leading in the Allergy Immunotherapies Industry

Some of the leading allergy immunotherapies market companies include ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG, among many others. For instance, in February 2024, researchers at McMaster University and the Denmark-based pharmaceutical company ALK-Abello A/S discovered a remarkable discovery, a novel cell that recalls allergies. The discovery provides scientists and researchers with a new target for treating allergies, potentially leading to new therapies. Also, in October 2024, Stallergenes Greer, a global leader in allergen immunotherapy (AIT), expanded into the Nordic region with the establishment of an affiliate dedicated to the Danish, Norwegian, and Swedish markets.

Global Allergy Immunotherapies Market Segmentation Coverage

• On the basis of the treatment type, the market has been bifurcated into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), wherein subcutaneous immunotherapy (SCIT) represented the largest segment. SCIT has a long-standing track record of efficacy and safety, supported by extensive clinical research and decades of use in treating allergic diseases such as hay fever, allergic asthma, and stings from insects. Moreover, the effectiveness of SCIT in reducing allergy symptoms and potentially modifying the natural course of allergic diseases contributes significantly to its dominance.
• Based on the allergy type, the market is categorized into allergic rhinitis, asthma, food allergy, venom allergy, and others, amongst which allergic rhinitis accounted for the largest market share primarily due to its high prevalence globally.
• On the basis of the distribution channel, the market has been divided into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, hospital pharmacy represented the largest segment. Primarily, hospital pharmacies are pivotal in administering and managing complex treatments that require close medical supervision, such as allergy immunotherapies, which often involve initial dosing under medical observation to monitor for adverse reactions.